Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Pericyte-like spreading by disseminated cancer cells activates YAP and MRTF for metastatic colonization.

Er EE, Valiente M, Ganesh K, Zou Y, Agrawal S, Hu J, Griscom B, Rosenblum M, Boire A, Brogi E, Giancotti FG, Schachner M, Malladi S, Massagué J.

Nat Cell Biol. 2018 Aug;20(8):966-978. doi: 10.1038/s41556-018-0138-8. Epub 2018 Jul 23.

PMID:
30038252
2.

Editorial overview: Cell signalling: Signal transduction to the nucleus, cytoskeleton, and organelles.

Thompson BJ, Giancotti FG.

Curr Opin Cell Biol. 2018 Apr;51:iv-vii. doi: 10.1016/j.ceb.2018.04.005. No abstract available.

PMID:
29753428
3.

Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis.

Cooper J, Xu Q, Zhou L, Pavlovic M, Ojeda V, Moulick K, de Stanchina E, Poirier JT, Zauderer M, Rudin CM, Karajannis MA, Hanemann CO, Giancotti FG.

Mol Cancer Ther. 2017 Aug;16(8):1693-1704. doi: 10.1158/1535-7163.MCT-16-0821. Epub 2017 May 3.

4.

Cancer: a new role for non-canonical Hippo signaling.

Cooper J, Giancotti FG.

Cell Res. 2017 Apr;27(4):459-460. doi: 10.1038/cr.2017.27. Epub 2017 Feb 28.

5.

Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets.

Chen YB, Xu J, Skanderup AJ, Dong Y, Brannon AR, Wang L, Won HH, Wang PI, Nanjangud GJ, Jungbluth AA, Li W, Ojeda V, Hakimi AA, Voss MH, Schultz N, Motzer RJ, Russo P, Cheng EH, Giancotti FG, Lee W, Berger MF, Tickoo SK, Reuter VE, Hsieh JJ.

Nat Commun. 2016 Oct 7;7:13131. doi: 10.1038/ncomms13131.

6.

Multi-organ Site Metastatic Reactivation Mediated by Non-canonical Discoidin Domain Receptor 1 Signaling.

Gao H, Chakraborty G, Zhang Z, Akalay I, Gadiya M, Gao Y, Sinha S, Hu J, Jiang C, Akram M, Brogi E, Leitinger B, Giancotti FG.

Cell. 2016 Jun 30;166(1):47-62. doi: 10.1016/j.cell.2016.06.009.

7.

Guido Tarone, Ph.D. (1951-2015).

Giancotti FG, Fässler R.

J Cell Sci. 2015 Aug 15;128(16):2955-6. No abstract available.

8.

Alan Hall 1952-2015.

Giancotti FG, Haynes CM, Machesky LM, Olson MF, Overholtzer M.

Nat Cell Biol. 2015 Jul;17(7):839-40. doi: 10.1038/ncb3190. Epub 2015 May 25. No abstract available.

PMID:
26005836
9.

The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT by restraining Ras-MAPK signalling.

Okada T, Sinha S, Esposito I, Schiavon G, López-Lago MA, Su W, Pratilas CA, Abele C, Hernandez JM, Ohara M, Okada M, Viale A, Heguy A, Socci ND, Sapino A, Seshan VE, Long S, Inghirami G, Rosen N, Giancotti FG.

Nat Cell Biol. 2015 Jan;17(1):81-94. doi: 10.1038/ncb3082. Epub 2014 Dec 22.

10.

Forward genetic screens in mice uncover mediators and suppressors of metastatic reactivation.

Gao H, Chakraborty G, Lee-Lim AP, Mavrakis KJ, Wendel HG, Giancotti FG.

Proc Natl Acad Sci U S A. 2014 Nov 18;111(46):16532-7. doi: 10.1073/pnas.1403234111. Epub 2014 Nov 5.

11.

Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.

Li W, Cooper J, Zhou L, Yang C, Erdjument-Bromage H, Zagzag D, Snuderl M, Ladanyi M, Hanemann CO, Zhou P, Karajannis MA, Giancotti FG.

Cancer Cell. 2014 Jul 14;26(1):48-60. doi: 10.1016/j.ccr.2014.05.001.

12.

Molecular insights into NF2/Merlin tumor suppressor function.

Cooper J, Giancotti FG.

FEBS Lett. 2014 Aug 19;588(16):2743-52. doi: 10.1016/j.febslet.2014.04.001. Epub 2014 Apr 12. Review.

13.

Deregulation of cell signaling in cancer.

Giancotti FG.

FEBS Lett. 2014 Aug 19;588(16):2558-70. doi: 10.1016/j.febslet.2014.02.005. Epub 2014 Feb 20. Review.

14.

Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas.

Karajannis MA, Legault G, Hagiwara M, Giancotti FG, Filatov A, Derman A, Hochman T, Goldberg JD, Vega E, Wisoff JH, Golfinos JG, Merkelson A, Roland JT, Allen JC.

Neuro Oncol. 2014 Jan;16(2):292-7. doi: 10.1093/neuonc/not150. Epub 2013 Dec 4.

15.

Mechanisms governing metastatic dormancy and reactivation.

Giancotti FG.

Cell. 2013 Nov 7;155(4):750-64. doi: 10.1016/j.cell.2013.10.029. Review.

16.

β4 Integrin signaling induces expansion of prostate tumor progenitors.

Yoshioka T, Otero J, Chen Y, Kim YM, Koutcher JA, Satagopan J, Reuter V, Carver B, de Stanchina E, Enomoto K, Greenberg NM, Scardino PT, Scher HI, Sawyers CL, Giancotti FG.

J Clin Invest. 2013 Feb;123(2):682-99. doi: 10.1172/JCI60720. Epub 2013 Jan 25.

17.

The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites.

Gao H, Chakraborty G, Lee-Lim AP, Mo Q, Decker M, Vonica A, Shen R, Brogi E, Brivanlou AH, Giancotti FG.

Cell. 2012 Aug 17;150(4):764-79. doi: 10.1016/j.cell.2012.06.035. Erratum in: Cell. 2012 Dec 7;151(6):1386-8.

18.

Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus.

Li W, Cooper J, Karajannis MA, Giancotti FG.

EMBO Rep. 2012 Mar;13(3):204-15. Review.

19.

Merlin/NF2 functions upstream of the nuclear E3 ubiquitin ligase CRL4DCAF1 to suppress oncogenic gene expression.

Cooper J, Li W, You L, Schiavon G, Pepe-Caprio A, Zhou L, Ishii R, Giovannini M, Hanemann CO, Long SB, Erdjument-Bromage H, Zhou P, Tempst P, Giancotti FG.

Sci Signal. 2011 Aug 23;4(188):pt6. doi: 10.1126/scisignal.2002314.

PMID:
21878678
20.

Integrin β4 signaling promotes mammary tumor cell adhesion to brain microvascular endothelium by inducing ErbB2-mediated secretion of VEGF.

Fan J, Cai B, Zeng M, Hao Y, Giancotti FG, Fu BM.

Ann Biomed Eng. 2011 Aug;39(8):2223-2241. doi: 10.1007/s10439-011-0321-6. Epub 2011 May 10.

21.

Back to the future: proceedings from the 2010 NF Conference.

Huson SM, Acosta MT, Belzberg AJ, Bernards A, Chernoff J, Cichowski K, Gareth Evans D, Ferner RE, Giovannini M, Korf BR, Listernick R, North KN, Packer RJ, Parada LF, Peltonen J, Ramesh V, Reilly KM, Risner JW, Schorry EK, Upadhyaya M, Viskochil DH, Zhu Y, Hunter-Schaedle K, Giancotti FG.

Am J Med Genet A. 2011 Feb;155A(2):307-21. doi: 10.1002/ajmg.a.33804. Epub 2010 Dec 22.

22.

Merlin's tumor suppression linked to inhibition of the E3 ubiquitin ligase CRL4 (DCAF1).

Li W, Giancotti FG.

Cell Cycle. 2010 Nov 15;9(22):4433-6. Epub 2010 Nov 15.

23.

Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib.

Rossi F, Yozgat Y, de Stanchina E, Veach D, Clarkson B, Manova K, Giancotti FG, Antonescu CR, Besmer P.

Mol Cancer Res. 2010 Sep;8(9):1271-83. doi: 10.1158/1541-7786.MCR-10-0065. Epub 2010 Aug 24.

24.

ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma.

Ammoun S, Cunliffe CH, Allen JC, Chiriboga L, Giancotti FG, Zagzag D, Hanemann CO, Karajannis MA.

Neuro Oncol. 2010 Aug;12(8):834-43. doi: 10.1093/neuonc/noq012. Epub 2010 Feb 11.

25.

Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus.

Li W, You L, Cooper J, Schiavon G, Pepe-Caprio A, Zhou L, Ishii R, Giovannini M, Hanemann CO, Long SB, Erdjument-Bromage H, Zhou P, Tempst P, Giancotti FG.

Cell. 2010 Feb 19;140(4):477-90. doi: 10.1016/j.cell.2010.01.029.

26.

Vascular endothelial growth factor enhances cancer cell adhesion to microvascular endothelium in vivo.

Shen S, Fan J, Cai B, Lv Y, Zeng M, Hao Y, Giancotti FG, Fu BM.

Exp Physiol. 2010 Feb;95(2):369-79. doi: 10.1113/expphysiol.2009.050260. Epub 2009 Oct 30.

27.

Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling.

López-Lago MA, Okada T, Murillo MM, Socci N, Giancotti FG.

Mol Cell Biol. 2009 Aug;29(15):4235-49. doi: 10.1128/MCB.01578-08. Epub 2009 May 18.

28.

Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling.

Pylayeva Y, Gillen KM, Gerald W, Beggs HE, Reichardt LF, Giancotti FG.

J Clin Invest. 2009 Feb;119(2):252-66. doi: 10.1172/JCI37160. Epub 2009 Jan 19.

29.

The c-Jun N-terminal kinase JNK functions upstream of Aurora B to promote entry into mitosis.

Oktay K, Buyuk E, Oktem O, Oktay M, Giancotti FG.

Cell Cycle. 2008 Feb 15;7(4):533-41.

PMID:
18431843
30.

Targeting integrin beta4 for cancer and anti-angiogenic therapy.

Giancotti FG.

Trends Pharmacol Sci. 2007 Oct;28(10):506-11. Epub 2007 Sep 5. Review.

PMID:
17822782
31.

Analysis of integrin signaling in genetically engineered mouse models of mammary tumor progression.

Pylayeva Y, Guo W, Giancotti FG.

Methods Enzymol. 2007;426:439-61. Review.

PMID:
17697895
32.

Tensin relief facilitates migration.

Pylayeva Y, Giancotti FG.

Nat Cell Biol. 2007 Aug;9(8):877-9. No abstract available.

PMID:
17671456
33.

Shedding light on Merlin's wizardry.

Okada T, You L, Giancotti FG.

Trends Cell Biol. 2007 May;17(5):222-9. Epub 2007 Apr 17. Review. Erratum in: Trends Cell Biol. 2008 Jan;18(1):11.

PMID:
17442573
34.

Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis.

Guo W, Pylayeva Y, Pepe A, Yoshioka T, Muller WJ, Inghirami G, Giancotti FG.

Cell. 2006 Aug 11;126(3):489-502.

35.

Development requires activation but not phosphorylation of beta1 integrins.

Pylayeva Y, Giancotti FG.

Genes Dev. 2006 May 1;20(9):1057-60. No abstract available.

36.
37.

Targeted deletion of the integrin beta4 signaling domain suppresses laminin-5-dependent nuclear entry of mitogen-activated protein kinases and NF-kappaB, causing defects in epidermal growth and migration.

Nikolopoulos SN, Blaikie P, Yoshioka T, Guo W, Puri C, Tacchetti C, Giancotti FG.

Mol Cell Biol. 2005 Jul;25(14):6090-102. Erratum in: Mol Cell Biol. 2005 Sep;25(17):7926.

38.

Netrin-integrin signaling in epithelial morphogenesis, axon guidance and vascular patterning.

Nikolopoulos SN, Giancotti FG.

Cell Cycle. 2005 Mar;4(3):e131-5. Epub 2005 Mar 18. Review.

PMID:
15725728
39.

Integrin beta4 signaling promotes tumor angiogenesis.

Nikolopoulos SN, Blaikie P, Yoshioka T, Guo W, Giancotti FG.

Cancer Cell. 2004 Nov;6(5):471-83.

40.

Integrin signalling during tumour progression.

Guo W, Giancotti FG.

Nat Rev Mol Cell Biol. 2004 Oct;5(10):816-26. Review.

PMID:
15459662
41.

Positional control of cell fate through joint integrin/receptor protein kinase signaling.

Giancotti FG, Tarone G.

Annu Rev Cell Dev Biol. 2003;19:173-206. Review.

PMID:
14570568
42.

Compartmentalization of integrin alpha6beta4 signaling in lipid rafts.

Gagnoux-Palacios L, Dans M, van't Hof W, Mariotti A, Pepe A, Meneguzzi G, Resh MD, Giancotti FG.

J Cell Biol. 2003 Sep 29;162(7):1189-96.

43.

A structural view of integrin activation and signaling.

Giancotti FG.

Dev Cell. 2003 Feb;4(2):149-51. Review.

44.

Alpha 5 beta 1 integrin activates an NF-kappa B-dependent program of gene expression important for angiogenesis and inflammation.

Klein S, de Fougerolles AR, Blaikie P, Khan L, Pepe A, Green CD, Koteliansky V, Giancotti FG.

Mol Cell Biol. 2002 Aug;22(16):5912-22.

45.

Defective Rac-mediated proliferation and survival after targeted mutation of the beta1 integrin cytodomain.

Hirsch E, Barberis L, Brancaccio M, Azzolino O, Xu D, Kyriakis JM, Silengo L, Giancotti FG, Tarone G, Fässler R, Altruda F.

J Cell Biol. 2002 Apr 29;157(3):481-92. Epub 2002 Apr 29.

46.

EGF-R signaling through Fyn kinase disrupts the function of integrin alpha6beta4 at hemidesmosomes: role in epithelial cell migration and carcinoma invasion.

Mariotti A, Kedeshian PA, Dans M, Curatola AM, Gagnoux-Palacios L, Giancotti FG.

J Cell Biol. 2001 Oct 29;155(3):447-58. Epub 2001 Oct 29.

47.

Gene correction of integrin beta4-dependent pyloric atresia-junctional epidermolysis bullosa keratinocytes establishes a role for beta4 tyrosines 1422 and 1440 in hemidesmosome assembly.

Dellambra E, Prislei S, Salvati AL, Madeddu ML, Golisano O, Siviero E, Bondanza S, Cicuzza S, Orecchia A, Giancotti FG, Zambruno G, De Luca M.

J Biol Chem. 2001 Nov 2;276(44):41336-42. Epub 2001 Aug 24.

48.

Integrin-specific activation of Rac controls progression through the G(1) phase of the cell cycle.

Mettouchi A, Klein S, Guo W, Lopez-Lago M, Lemichez E, Westwick JK, Giancotti FG.

Mol Cell. 2001 Jul;8(1):115-27.

49.

CD104.

Dans M, Giancotti FG.

J Biol Regul Homeost Agents. 2001 Apr-Jun;15(2):193-6. No abstract available.

PMID:
11501983
50.

Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling.

Sumitomo M, Shen R, Walburg M, Dai J, Geng Y, Navarro D, Boileau G, Papandreou CN, Giancotti FG, Knudsen B, Nanus DM.

J Clin Invest. 2000 Dec;106(11):1399-407.

Supplemental Content

Loading ...
Support Center